

(19) World Intellectual Property Organization  
International Bureau



29 SEP 2004



(43) International Publication Date  
27 November 2003 (27.11.2003)

PCT

(10) International Publication Number  
**WO 03/096992 A2**

(51) International Patent Classification<sup>7</sup>: **A61K**

(21) International Application Number: PCT/US03/15995

(22) International Filing Date: 16 May 2003 (16.05.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
10/150,619 17 May 2002 (17.05.2002) US

(71) Applicant (for all designated States except US): **THE REGENTS OF THE UNIVERSITY OF CALIFORNIA** [US/US]; 1111 Franklin Street, 12th Floor, Oakland, CA 94607 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CARSON, Dennis, A.** [US/US]; 9728 Keeneland Row, La Jolla, CA 92307

(US). **LEONI, Lorenzo, M.** [CH/US]; 3908 Via Tranquilo, San Diego, CA 92122 (US). **COTTAM, Howard, B.** [US/US]; 3144 Willow Creek Place, Escondido, CA 92027 (US).


(74) Agents: **ACKERMAN, Joel, G.** et al.; Townsend and Townsend and Crew LLP, Two Embarcadero Center, Eighth Floor, San Francisco, CA 94111 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),

[Continued on next page]

(54) Title: TREATMENT OF CANCER WITH MEFLOROQUINE, ITS PURIFIED ENANTIOMERS, AND MEFLOROQUINE ANALOGS



(57) Abstract: Cancers, particularly solid tumors (e.g., breast, lung, renal, colon and ovarian cancers and melanomas) and cancers of the hematologic system, e.g., hemopoietic cancers such as leukemias, lymphomas or myelomas, are treated by administration of a therapeutically effective amount of a compound having the formula (I): (I) in which the quinoline ring is substituted by from one to three groups selected from halogen and trifluoromethyl (designated in the formula by "A"), and is optionally further substituted by one or more other moieties and R is (a) NR<sub>1</sub>R<sub>2</sub> in which R<sub>1</sub> and R<sub>2</sub> are independently hydrogen or C1-C4 alkyl; (b) 2-piperidyl, (c) 2-pyridyl, and (d) 5-(ethyl or vinyl)-quinuclidin-4-yl; an enantiomer of such a compound; a pharmaceutically acceptable salts of such a compound or of an enantiomer thereof; a prodrug of such a compound or of an enantiomer thereof; a metabolite of such a compound or of an enantiomer thereof; and mixtures of two or more of the foregoing. A particularly preferred compound is mefloquine.



WO 03/096992 A2